SEC-sourced researchBeta
BBIO
BridgeBio Pharma, Inc.
Company comparison ↗
Data passport
- CIK
- 0001743881
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Sep 21, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 9,303,000.0000 | Feb 24, 2026 |
| December 2024 | 221,902,000.0000 | Feb 24, 2026 |
| December 2025 | 502,076,000.0000 | Feb 24, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 502,076,000.0000 | -732,938,000.0000 | -445,910,000.0000 | 936,025,000.0000 | 3,012,606,000.0000 | Feb 24, 2026 |
| December 2024 | 221,902,000.0000 | -543,347,000.0000 | -520,726,000.0000 | 919,338,000.0000 | 2,376,950,000.0000 | Feb 24, 2026 |
| December 2023 | 9,303,000.0000 | -653,251,000.0000 | -527,720,000.0000 | — | — | Feb 24, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $502.08M | December 2025 | Feb 24, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $221.9M | December 2024 | Feb 24, 2026 | 10-K |
| Net incomeProfitLoss | -$732.94M | December 2025 | Feb 24, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$445.91M | December 2025 | Feb 24, 2026 | 10-K |
| Total assetsAssets | $936.03M | December 2025 | Feb 24, 2026 | 10-K |
| Total liabilitiesLiabilities | $3.01B | December 2025 | Feb 24, 2026 | 10-K |